Literature DB >> 4005116

Concentration-effect relationship of oxprenolol in healthy volunteers: a retrospective analysis.

A Racine-Poon, J Moppert.   

Abstract

A mathematical model describing the relationship between plasma concentrations of oxprenolol and submaximal-exercise heart rates has been developed on the basis of data available from 34 healthy volunteers. This relationship, which is exponential in type, is consistent with the 'law of diminishing returns', and is independent of the pharmaceutical formulations used; it appears to be established instantaneously, and is not modified by repeated drug administration over 8 days. At oxprenolol concentrations of 190-250 ng/ml, between half and three-quarters of the subjects investigated reached 90% of their estimated maximum levels of beta-adrenoceptor blockade.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005116      PMCID: PMC1463767          DOI: 10.1111/j.1365-2125.1985.tb02755.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography.

Authors:  P H Degen; W Riess
Journal:  J Chromatogr       Date:  1976-06-09

2.  Detection of carriers of inherited disorders.

Authors:  R G Davidson
Journal:  Birth Defects Orig Artic Ser       Date:  1976

Review 3.  The assessment of beta-adrenoceptor blocking drugs in man.

Authors:  D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

4.  Ineffectiveness of beta-adrenergic blockers on ventilatory response to carbon dioxide.

Authors:  Y Twum-Barima; D Ahmad; J T Hamilton; S G Carruthers
Journal:  Clin Pharmacol Ther       Date:  1982-09       Impact factor: 6.875

Review 5.  Kinetics of pharmacologic response.

Authors:  N H Holford; L B Sheiner
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

6.  Initiation and maintenance of beta-blockade with intravenous oxprenolol.

Authors:  B Silke; V A John; R T Calvert; S H Taylor
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 7.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

8.  Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.

Authors:  D G McDevitt; H C Brown; S G Carruthers; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

9.  A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.

Authors:  K L Woods; D B Jack; M J Kendall; A Halsey; M L O'Donnell; S J Warrington; V A John
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

10.  Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.

Authors:  P N Bennett; J Bennett; I Bradbrook; J Francis; V A John; H Rogers; P Turner; S J Warrington
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

View more
  4 in total

1.  Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Pharmacokinetic-pharmacodynamic modelling of oxprenolol in man using continuous non-invasive blood pressure monitoring.

Authors:  R Koopmans; B Oosterhuis; J M Karemaker; J Wemer; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers.

Authors:  A L van Steveninck; M S Pieters; H C Schoemaker; D D Breimer; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

4.  Concentration-effect relationships for oxprenolol in patients with essential hypertension.

Authors:  G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.